|
N-(5-tert-Butylisoxazol-3-yl)-N’-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt |
|---|---|
| Trade Name | |
| Orphan Indication | Acute myeloid leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2009-03-18 00:00:00 |
| Sponsor | Daiichi Sankyo, Inc.;211 Mount Airy Road;Basking Ridge, New Jersey, 07920 |
